Association between Hyperglycemia and Medication-Related Osteonecrosis of the Jaw (MRONJ)

被引:2
|
作者
Kammerhofer, Gabor [1 ,2 ]
Vegh, Daniel [2 ,3 ]
Banyai, Dorottya [2 ,4 ]
Vegh, Adam [2 ,5 ]
Joob-Fancsaly, Arpad [1 ,2 ]
Hermann, Peter [2 ,3 ]
Geczi, Zoltan [2 ,3 ]
Hegedus, Tamas [2 ,3 ]
Somogyi, Kata Sara [2 ,3 ]
Bencze, Bulcsu [2 ,3 ]
Biczo, Zita [1 ,2 ]
Juhasz, Donat Huba [2 ,6 ]
Zaborszky, Peter [2 ,6 ]
Ujpal, Marta [1 ,2 ]
Vaszilko, Mihaly Tamas [1 ,2 ]
Nemeth, Zsolt [1 ,2 ]
机构
[1] Semmelweis Univ, Dept Oromaxillofacial Surg & Stomatol, H-1088 Budapset, Hungary
[2] Semmelweis Univ, Diabet Dent Working Grp, H-1088 Budapest, Hungary
[3] Semmelweis Univ, Dept Prosthodont, H-1088 Budapset, Hungary
[4] Semmelweis Univ, Dept Paediat Dent & Orthodont, H-1088 Budapset, Hungary
[5] Semmelweis Univ, Dept Oral Diagnost, H-1088 Budapest, Hungary
[6] Semmelweis Univ, Fac Dent, H-1088 Budapest, Hungary
关键词
diabetes; hyperglycemia; osteonecrosis; bisphosphonates; oral surgery; SURGEONS POSITION PAPER; AMERICAN ASSOCIATION; CANCER; THERAPY; RISK; DENOSUMAB;
D O I
10.3390/jcm12082976
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Medication-related osteonecrosis of the jaw (MRONJ) is a type of jawbone necrosis caused by the use of drugs for some types of cancer and osteoporosis. The current study aimed to evaluate the associations between hyperglycemia and the development of medication-related osteonecrosis of the jaw. Methods: Our research group investigated data collected between 1 January 2019 and 31 December 2020. A total of 260 patients were selected from the Inpatient Care Unit, Department of Oromaxillofacial Surgery and Stomatology, Semmelweis University. Fasting glucose data were used and included in the study. Results: Approximately 40% of the necrosis group and 21% of the control group presented with hyperglycemia. There was a significant association between hyperglycemia and MRONJ (p < 0.05, p = 0.003). Vascular anomaly and immune dysfunction caused by hyperglycemia can lead to necrosis after tooth extraction. Necrosis is more common in the mandible (75.0%) and in the case of parenteral antiresorptive treatment (intravenous Zoledronate and subcutaneous Denosumab). Hyperglycemia is a more relevant risk factor than bad oral habits (26.7%). Conclusions: Ischemia is a complication of abnormal glucose levels, a possible risk factor for necrosis development. Hence, uncontrolled or poorly regulated plasma glucose levels can significantly increase the risk of jawbone necrosis after invasive dental or oral surgical interventions.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Comparison of the Effects of Four Laser Wavelengths on Medication-Related Osteonecrosis of the Jaw (MRONJ) in a Murine Model: An In Vivo Photobiomodulation Study
    Ayhan, Mustafa
    Gedik, Betul
    Kalelioglu, Ekrem Emir
    Kundakcioglu, Abdulsamet
    Kucukgergin, Canan
    Turgut, Cevat Tugrul
    Kocaelli, Humeyra
    Alatli, Fatma Canan
    Issever, Halim
    Ademoglu, Evin
    Yaltirik, Mehmet
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2024, 21 (15): : 2959 - 2973
  • [42] Macrophage Involvement in Medication-Related Osteonecrosis of the Jaw (MRONJ): A Comprehensive, Short Review
    Gkouveris, Ioannis
    Soundia, Akrivoula
    Gouveris, Panagiotis
    Zouki, Dionysia
    Hadaya, Danny
    Tetradis, Sotirios
    CANCERS, 2022, 14 (02)
  • [43] Dental implants as risk factors for patients with medication-related osteonecrosis of the jaws (MRONJ)
    Pichardo, S. E. C.
    van der Hee, J. G.
    Fiocco, M.
    Appelman-Dijkstra, N. M.
    van Merkesteyn, J. P. R.
    BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 2020, 58 (07) : 771 - 776
  • [44] Medication-related Osteonecrosis of the Jaw: A Review
    AlDhalaan, Nouf A.
    BaQais, Asma
    Al-Omar, Ahmad
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (02)
  • [45] Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis
    Bagan, J.
    Peydro, A.
    Calvo, J.
    Leopoldo, M.
    Jimenez, Y.
    Bagan, L.
    ORAL DISEASES, 2016, 22 (04) : 324 - 329
  • [46] The Role of Platelet-Rich Fibrin (PRF) in the Prevention of Medication-Related Osteonecrosis of the Jaw (MRONJ)
    Miranda, Michele
    Gianfreda, Francesco
    Raffone, Carlo
    Antonacci, Donato
    Pistilli, Valeria
    Bollero, Patrizio
    BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [47] Medication-related osteonecrosis of the jaw (MRONJ): Bisphosphonates, antiresorptives, and antiangiogenic agents. What next?
    Mupparapu, Mel
    QUINTESSENCE INTERNATIONAL, 2016, 47 (01): : 7 - 8
  • [48] Chinese expert consensus on the diagnosis and clinical management of medication-related osteonecrosis of the jaw
    Ruan, Han-Jin
    Chen, Heng
    Hou, Jin-Song
    An, Jin-Gang
    Guo, Yu-Xing
    Liu, Bing
    Tian, Lei
    Pan, Jian
    Li, Jin-Song
    Jiang, Can-Hua
    Tian, Zhen
    Xu, Jie
    Zhu, Ling
    Sun, Chang-Fu
    Zhi, Ke-Qian
    Qu, Qing
    Zong, Chun-Lin
    Li, Meng-Yu
    Zhang, Zhi-Yuan
    He, Yue
    JOURNAL OF BONE ONCOLOGY, 2024, 49
  • [49] Medication-Related Osteonecrosis of the Jaw: A Critical Narrative Review
    Lorenzo-Pouso, Alejandro, I
    Bagan, Jose
    Bagan, Leticia
    Gandara-Vila, Pilar
    Chamorro-Petronacci, Cintia M.
    Castelo-Baz, Pablo
    Blanco-Carrion, Andres
    Angeles Blanco-Fernandez, Maria
    Alvarez-Calderon, Oscar
    Carballo, Javier
    Perez-Sayans, Mario
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (19)
  • [50] Fat Graft in Surgical Treatment of Medication-Related Osteonecrosis of the Jaws (MRONJ)
    De Cicco, Davide
    Tartaro, Gianpaolo
    Colella, Giuseppe
    Dell'Aversana Orabona, Giovanni
    Santagata, Mario
    Ferrieri, Ivo
    Troiano, Antonio
    Stagliano, Samuel
    Volgare, Andrea Salvatore
    D'Amato, Salvatore
    APPLIED SCIENCES-BASEL, 2021, 11 (23):